Streetbeat News

Analyst Ratings

AGL

Truist Securities analyst Jailendra Singh has maintained a 'Buy' rating on Agilon Health (NYSE:AGL) but lowered the price target from $27 to $23.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:49 pm

VCEL

Truist Securities analyst Samuel Brodovsky maintains a 'Hold' rating on Vericel (NASDAQ:VCEL) and raises the price target from $33 to $39.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:47 pm

SVM

Silvercorp Metals reported Q2 earnings of $0.07 per share, beating the analyst consensus estimate of $0.05 by 40%. The company also reported quarterly sales of $53.99 million, surpassing the analyst consensus estimate of $51.10 million by 5.66%. Both earnings and sales have increased compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:46 pm

MODG

Truist Securities analyst Michael Swartz maintains a 'Buy' rating on Topgolf Callaway Brands (NYSE:MODG) but lowers the price target from $25 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:46 pm

SEAS

Truist Securities analyst Michael Swartz maintains a 'Buy' rating on SeaWorld Entertainment (NYSE:SEAS) and raises the price target from $55 to $58.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:44 pm

PNTG

Truist Securities analyst David Macdonald maintains a 'Hold' rating on Pennant Gr (NASDAQ:PNTG) and raises the price target from $13 to $14.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:42 pm

ODD

Truist Securities has maintained a 'Buy' rating on ODDITY Tech and raised the price target from $54 to $55. The report was released on 8th Nov 2023.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:41 pm

NTBL

Notable Labs (NASDAQ:NTBL) has published data from an ex vivo study demonstrating the potential of its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML). The study found that tretinoin, a standard-of-care agent in acute promyelocytic leukemia (APL), enhanced the ex vivo effects of FLA and AZA, suggesting a potential rationale for use of CD38-targeting agents to further enhance the envisioned treatment effect.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:41 pm

IBP

Truist Securities analyst Keith Hughes has maintained a 'Buy' rating on Installed Building Products (NYSE:IBP) but lowered the price target from $170 to $160.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:40 pm

HLLY

Truist Securities analyst Michael Swartz maintains a 'Buy' rating on Holley (NYSE:HLLY) but lowers the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:38 pm